Meet the team behind LifeView testing

Kelly Ketterson, our CEO, is an award winning leader with a proven track record in the IVF industry and a strong commitment to advancing education in women’s healthcare. Her dedication to expanding knowledge and establishing new benchmarks is showcased in her role as Vice President of Clinical Operations at CooperSurgical, where she spearheaded the creation of the US Center of Excellence, developed an impactful embryology training program and sales support program. Before joining CooperSurgical, Kelly served as Chief Operating Officer of Althea Science and Reprogenetics, and she played a pivotal role as a founder of Recombine, Inc. Both Reprogenetics and Recombine were successfully acquired by CooperSurgical, Inc., further demonstrating her influence in the field.

Nathan R. Treff is Co-founder, Chief Scientific Officer, and Clinical Lab Director of Genomic Prediction. His career has been devoted to developing innovative and effective methods of reproductive genetic testing for IVF patients. He completed postdoctoral fellowships at the University of Wisconsin-Madison in embryonic stem cells and the Serono Research Institute in reproductive biology. He is an Associate Professor at Rutgers University Robert Wood Johnson Medical School, where he teaches reproductive genetics. Nathan is the recipient of 8 ASRM Prize Paper Awards, the ASRM New Investigator Award, and the Bonei Olam Scientific Achievement Award. He has published over 120 peer-reviewed papers in reproductive genetics. He served as a Member of the ASRM Research Committee, a Senior Associate Editor of JARG, and an Editor of Fertility and Sterility and is currently Associate Editor of Fertility and Sterility Science. He holds a PhD in Biochemistry from Washington State University and an HCLD in Molecular Diagnostics from the American Board of Bioanalysis.

Jia is Chief Technological Officer, a seasoned domain expert and leader in the genomics space. Jia holds a PhD in Biomedical Engineering and has 13 years of experience in next-generation sequencing with 20+ papers published in high-impact journals. Because of her unique industry experience, she harbored cross-domain knowledge from project management, software development, bioinformatics to cancer genomics, and personalized medicine. Before joining Genomic Prediction, she led a cross-functional development team in IBM Watson Health for clinical variant interpretation and played a pivotal role in strategic roadmap planning and client support.

As the Chief Commercial Officer of Genomic Prediction, Marsha brings extensive experience in driving growth and innovation within the biotechnology sector, with a particular focus on guiding start-ups and emerging companies through critical development phases. She is a highly accomplished and dynamic biotechnology executive with a passion for supporting infertility awareness and genetics research, having done her graduate work in the field of micromolecular genetics. Marsha thrives in entrepreneurial business environments, achieving strong market growth and has received numerous awards for her contributions to the healthcare industry. Her dedication to advancing life science technologies is deeply rooted in a desire to improve patient outcomes, advocacy, and access to care. Marsha is committed to fostering a culture of innovation, excellence, and collaboration with fertility partners to support patients on their journey to parenthood.